Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review
Authors
Keywords
-
Journal
Frontiers in Psychiatry
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-07-12
DOI
10.3389/fpsyt.2022.917199
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes
- (2022) Grant M Jones et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: a systematic review
- (2021) Bruno Romeo et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics
- (2021) Cato M. H. de Vos et al. Frontiers in Psychiatry
- Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer
- (2020) Gabrielle I Agin-Liebes et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Emotions and brain function are altered up to one month after a single high dose of psilocybin
- (2020) Frederick S. Barrett et al. Scientific Reports
- Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis
- (2020) Bruno Romeo et al. JOURNAL OF PSYCHOPHARMACOLOGY
- A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses
- (2020) Tingying Chi et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies
- (2020) Kristoffer A. A. Andersen et al. ACTA PSYCHIATRICA SCANDINAVICA
- Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial
- (2020) Rebecca L Rothberg et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder
- (2019) Sabine Aust et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Psychedelic medicine: The biology underlying the persisting psychedelic effects
- (2019) K.P.C. Kuypers MEDICAL HYPOTHESES
- Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory
- (2019) Leor Roseman et al. JOURNAL OF PSYCHOPHARMACOLOGY
- RoB 2: a revised tool for assessing risk of bias in randomised trials
- (2019) Jonathan A C Sterne et al. BMJ-British Medical Journal
- Classical psychedelics for the treatment of depression and anxiety: A systematic review
- (2019) Silvia Muttoni et al. JOURNAL OF AFFECTIVE DISORDERS
- Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
- (2019) Friederike Holze et al. NEUROPSYCHOPHARMACOLOGY
- A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study
- (2018) E. Dakwar et al. NEUROPHARMACOLOGY
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
- (2018) Fernanda Palhano-Fontes et al. PSYCHOLOGICAL MEDICINE
- Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression
- (2018) Leor Roseman et al. Frontiers in Pharmacology
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
- (2017) R. L. Carhart-Harris et al. PSYCHOPHARMACOLOGY
- Psychedelics as Medicines: An Emerging New Paradigm
- (2016) DE Nichols et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI)
- (2016) Matthew M. Nour et al. Frontiers in Human Neuroscience
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
- (2016) Roland R Griffiths et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
- (2016) Stephen Ross et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Alterations of consciousness and mystical-type experiences after acute LSD in humans
- (2016) Matthias E. Liechti et al. PSYCHOPHARMACOLOGY
- Long-term follow-up of psilocybin-facilitated smoking cessation
- (2016) Matthew W. Johnson et al. AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE
- Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
- (2015) Frederick S Barrett et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
- (2015) Michael P Bogenschutz et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
- (2014) Matthew W Johnson et al. JOURNAL OF PSYCHOPHARMACOLOGY
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
- (2009) Alessandro Liberati et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now